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Background:Thereisincreasingevidencethatglialcellsplayaroleinthepathomechanisms
of mood disorders and the mode of action of antidepressant drugs. Methods:To examine
whether there is a direct effect on the expression of different genes encoding proteins that
have been implicated in the pathophysiology of affective disorders, primary astrocyte cell
cultures from rats were treated with two different antidepressant drugs, imipramine and
escitalopram, and the RNA expression of brain-derived neurotrophic factor (Bdnf), sero-
tonin transporter (5Htt), dopamine transporter (Dat), and endothelial nitric oxide synthase
(Nos3) was examined. Results: Stimulation of astroglial cell culture with imipramine, a
tricyclic antidepressant, led to a signiﬁcant increase of the Bdnf RNA level whereas treat-
ment with escitalopram did not. In contrast, 5Htt was not differentially expressed after
antidepressant treatment. Finally, neither Dat nor Nos3 RNA expression was detected in
cultured astrocytes. Conclusion:These data provide further evidence for a role of astroglial
cells in the molecular mechanisms of action of antidepressants.
Keywords: antidepressant, mechanism of action, BDNF, nitric oxide synthase, gene expression, depression, glia,
astrocytes
INTRODUCTION
Majordepressivedisorder(MDD)isoneofthemostprevalentpsy-
chiatric disorders. Its debilitating long-term course causes severe
psychosocial consequences in the affected individuals and a high
economic burden. More patients than previously thought do not
completely recover and display permanent depressive symptoms
and even persisting cognitive deﬁcits (Manji et al.,2000; Pittenger
and Duman, 2008). Worldwide up to 15% of a given popula-
tion,women more often than men,experience a major depressive
episode at least once in a lifetime (Bromet et al., 2011) and 50%
of the patients who had one depressive episode will suffer from
recurrent depressive episodes (Kupfer, 1991). About 11% of indi-
viduals suffering from a mood disorder were found to commit
suicide(Angstetal.,2005).Theheritabilityof MDDwasestimated
at about 37% (Sullivan et al., 2000), adding evidence to its com-
plex etiology. While not only the molecular mechanisms of MDD
are still elusive, also the downstream mechanisms of the mode of
actionof antidepressantsremainuncertain;whiletheprimarytar-
gets are well known, subsequent molecular processes underlying
thedelayedclinicaleffectsarenot.Recentresearchpointedtoward
animportantroleofglialpathologyinmooddisorders(Rajkowska
and Miguel-Hidalgo, 2007). Post-mortem studies found alter-
ations in density and protein expression of astrocytes (Ongur
et al., 1998), a decrease in the number of glial cells in certain
brain regions (Cotter et al.,2001),and an enlargement of glial cell
bodies (Rajkowska et al., 1999) in brains of individuals suffering
fromamooddisorder.Acomparisonof post-mortembrain-tissue
ofyoungerandolderpatientssufferingfromMDDshowedthat,in
older subjects, a reduction in pyramidal neurons could be found
whereas in younger subjects only subtle neuronal damage but a
prominent astroglial pathology could be found (Rajkowska and
Miguel-Hidalgo,2007).Thisraisesthequestionifinmajordepres-
sionthereisaprimarydysfunctioninglialcellswhichthenleadsto
alterationsinneuronalcells.Aclinicalstudyfoundincreasedlevels
of the glial marker S100 B in depressed patients which decreased
slightly after treatment whereas the marker for neuronal dam-
age,neuron speciﬁc enolase,did not differ in patients and healthy
controls, emphasizing the important role of glial cells in mood
disorders (Schroeter et al., 2010). A recent study found a possi-
ble role for human astroglial cells as stem cells as they developed
a neuronal phenotype after incubation with imipramine (Cabras
et al., 2010). Astrocytes therefore have multiple functions: they
modulate neuroplasticity through secretion of neurotrophic fac-
torslikebrain-derivedneurotrophicfactor(BDNF),removeexcess
glutamate from the synaptic cleft to protect neurons from its neu-
rotoxic effects (Lobsiger and Cleveland, 2007) and play a role in
neurotransmitter trafﬁcking. These and other ﬁndings lead to the
model of the so called tripartite glutamatergic synapse consisting
of the pre- and postsynaptic neurons and a surrounding astro-
cyte(Araqueetal.,1999).Mostinterestingly,ketamine,anNMDA
antagonist,wasrecentlyfoundtodisplayantidepressantproperties
with a rapid onset of action (Maeng and Zarate, 2007). Whether
www.frontiersin.org April 2012 | Volume 3 | Article 33 | 1Kittel-Schneider et al. Antidepressant-induced expression of Bdnf in astrocytes
astroglia play a role in the antidepressant potency of ketamine
is not clear, but it has been described that the acute adminis-
tration of ketamine increases BDNF protein levels in the mouse
brain. This study was focused on hippocampal neurons but sim-
ilar mechanisms might take place in astroglial cells (Autry et al.,
2011).
To eventually improve the therapy of MDD it thus justiﬁed
to accrue deeper knowledge about the role of astrocytes in this
disorder,withemphasisontheirroleinthemechanismsof antide-
pressant treatment. Here we investigated whether genes suggested
to play an important role in the pathophysiology of affective
disorders are differentially expressed in cultured astrocytes incu-
batedwithantidepressantagents.Brain-derivedneurotrophicfac-
tor (Bdnf), the serotonin transporter (5Htt), and the dopamine
transporter (Dat) genes were examined due to the large body
of evidence suggesting an important role for those molecules in
affective disorders (Levinson, 2006; Brunoni et al., 2008). Most
importantly, their gene products, the dopamine, and the sero-
tonin transporter,are the primary targets of antidepressant agents
(Nieuwstraten and Dolovich, 2001; White et al., 2005; Watanabe
et al., 2011). BDNF is thought to mediate the long-term effects
of antidepressants by inﬂuencing neuronal plasticity and is cen-
tral to the neurotrophin hypothesis of depression (Vaidya and
Duman, 2001; Castren and Rantamaki, 2010). Furthermore, as
we showed in previous studies that Nos3 knock-out mice dis-
playdecreasedadultneurogenesisandreducedresponsivenessina
learnedhelplessnessparadigm(Reifetal.,2004),andaswedemon-
strated an association of a polymorphism in the NOS3 gene with
bipolar disorder (Reif et al., 2006), we speculated that the expres-
sion of NOS3 might also play a role in the mode of action of
psychiatric medication and might be differentially regulated after
incubation with antidepressants as well. Imipramine and escitalo-
pram were chosen as antidepressants to contrast the broader (yet
more noradrenergic) mode of action of the tricyclic compound
imipramine to the highly selective serotonin reuptake inhibitor
(SSRI) escitalopram.
MATERIALS AND METHODS
ASTROCYTE CELL CULTURE
Primary astrocytes were isolated and cultured according to a
method previously described with minor modiﬁcations (Deu-
mens et al., 2004). In short, neonatal (postnatal day 1) Lewis
rat pups were decapitated and the neocortex was dissected and
cleared of meninges. The tissue was diced in small fragments
and subsequently dissociated by passage through a nylon screen
(100μm mesh size). The suspension was centrifuged for 10min
at 1200rpm, the supernatant discarded, and the pellet resus-
pended in 1ml culture medium (Dulbecco’s Modiﬁed Eagles
Medium containing glutamax-I, supplemented with 10% fetal
calf serum, 100U/ml penicillin, and 100μg/ml streptomycin).
Cells were plated into 25cm2 cell culture ﬂasks at a density of
106 living cells per ﬂask and incubated at 37°C and 5% CO2.
Culture medium was refreshed after 4–5days and every 2days
thereafter. Conﬂuence was reached after 10–12days, after which
contaminating cells (predominantly neurons and microglia) were
removed by shaking the culture ﬂasks at 135rpm on a gyratory
shaker for 2days. Purity of cultures was checked and proved
that>95% of cells were GFAP immunopositive astrocytes. After
puriﬁcation, cells were subcultured (ratio 1:2) in 25cm2 cell cul-
ture ﬂasks. Medium was refreshed every 2–3days. Cultures were
passedtwicetoobtainsufﬁcientamountofcells.Stocksolutionsof
5mM of escitalopram hydrochloride (Lundbeck A/S,Valby, Den-
mark)andimipramine(Sigma-AldrichChemie,Zwijndrecht,The
Netherlands) were freshly prepared in sterile H2O and protected
from light. Medium was refreshed a few hours before addition of
antidepressants. Final concentrations were 50 or 100μM.
The concentrations of 50 and 100μM were chosen based on
plasmalevelsduringantidepressanttreatment,andonthefactthat
antidepressantsareconcentrated(upto10-fold)inthebrain.Fur-
thermorewekeptinmindthatconcentrationsof pharmacological
agents used in cell culture experiments generally have to be higher
as those encountered in in vivo situations due to the nature of
cell culture conditions. Sterile H2O served as corresponding con-
trol. The incubation lasted 4h to examine the acute effects of the
antidepressant treatment.
To examine effects of chronic treatment, an incubation period
of 24h incubation was also investigated but there were no sig-
niﬁcant differences in RNA expression as compared to the control
condition(datanotshown).Thecompleteexperimentconsistedof
three different batches of primary astrocytes, where every culture
condition was performed in triplicate. RNA was extracted from
each cell culture sample and two sets of cDNA were transcribed
from each RNA, resulting in six sets of cDNA were transcribed
from each triplicate.
ASSESSMENTS OF Bdnf, 5Htt, Dat, AND Nos3 RNA EXPRESSION AND
STATISTICAL ANALYSIS
After exposure to antidepressants, cells were washed twice with
PBS Buffer and lysed in 175μl of Buffer RLN provided by the
RNeasyMiniKit(Qiagen,Hilden,Germany)thatwasusedtosub-
sequently isolate total RNA. The RNA was reversed transcribed
using the iScript™ cDNA Synthesis Kit (Biorad, Hercules, USA).
Real Time PCR was performed using the iCycler iQ™ Optical
Module (Biorad, Hercules, USA). The optimization of the Real
Time PCR reaction was performed according to the manufac-
turer’sinstructionsbutscaleddownto25μlperreaction.Standard
PCRconditionswereused(iQ™SYBR®GreenSupermixprotocol)
and all reagents were provided in the iQ SYBR Green Supermix,
including iTaq DNA polymerase (Biorad, Hercules, USA). Ribo-
somal 18S,Gapdh,and Arp were used to normalize each template
using the normalization software GeNorm (Vandesompele et al.,
2002). Standard curves for each ampliﬁcation product were gen-
erated from 10-fold dilutions of pooled cDNA amplicons isolated
fromgelelectrophoresis.Forprimersequences,seeTable 1 (MWG
Biotech AG, Ebersberg, Germany).
RESULTS
Wedetectedsigniﬁcantlevelsof Bdnf and5Htt RNAexpressionin
astrocytes under standard cell culture conditions,but were unable
to measure Dat or Nos3 expression in any of the examined cell
culture samples. Consistent with our hypothesis that antidepres-
sant agents display a stimulatory effect on BDNF, quantitative
PCR analysis demonstrated that the relative levels of Bdnf RNA
expression in astrocytes were signiﬁcantly increased when treated
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T a b l e1|P r imer sequences for quantitative PCR analysis.
Gene Sense primer Antisense primer
Bdnf 5 -TGC CGC AAA CAT GTC
TAT GAG G-3 
5 -GCT GTG ACC CAC TCG CTA
ATA C-3 
5Htt 5 -GAC AGC CAC CTT CCC
TTA CA-3 
3 -CTA GCA AAC GCC AGG AGA
AC-5 
Nos3 5 -CCTTCC GCT ACC AGC
CAG A-3 
5 -CAG AGA TCT TCA CTG CAT
TGG CTA-3 
Gapdh 5 -AAC GAC CCCTTC ATT
GAC-3 
5 -TCC ACG ACA TAC TCA GCA
C-3 
Arp 5 -CGA CCT GGA AGT
CCA ACT AC-3 
5 -ATCTGCTGC ATCTGCTTG-3 
18S 5 -GAA ACT GCG AAT
GGCTCATTA AA-3 
5 -CCA CAG TTA TCC AAG TAG
GAG AGG A-3 
The results of six sets of cDNA were pooled together, tested for normal distribu-
tion with the Shapiro–Wilk- and the Kolmogorov–Smirnow-test and then analyzed
for statistical signiﬁcance with non-parametric Kruskal–Wallis-test using SPSS
software version V19 (IBM
® SPSS
® Statistics V19, 2010, Armonk, USA).
FIGURE 1 | Imipramine but not escitalopram increases the expression
of Bdnf RNA in rat astrocyte cell cultures.The cells were incubated for
4h with either 50μM escitalopram (E), 50μM imipramine (I), or 100μM
imipramine (I). RNA levels of Bdnf were analyzed by quantitative real time
PCR. Results are expressed as relative levels after normalization against
housekeeping genes (Gapdh, Arp, and 18S) in percentages of control cells
and represent the means of six independent experiments±SD. Data were
statistically analyzed using non-parametric Kruskal–Wallis-Test.
***p <0.001.
with either 50 (p <0.001) or 100μM( p <0.001) imipramine as
compared to control cells treated with vehicle. The escitalopram-
treated astrocytes showed a nominal,but non-signiﬁcant increase
in Bdnf RNA expression (Figure 1). Expressed as % of controls,
the RNA level of Bdnf was signiﬁcantly increased in the astro-
cytes incubated with 50 or 100μM imipramine (100.4±12.0
and 113.7±4.4% of controls), while only a nominal but non-
signiﬁcant increase was observed in cells treated with 50μM
escitalopramafter4h(57.6±8.0%of controls).Theculturedcells
were also treated with 50μM of both substances for 24h; here,no
signiﬁcant changes in RNA expression were observed (data not
shown). Tests to examine the BDNF protein levels are a subject to
further studies.
As the primary molecular target of tricyclic antidepressants
and SSRIs is (besides others) the serotonin transporter, we spec-
ulated that the RNA expression of 5Htt would be differentially
regulated in cultured, treated astrocytes. While we detected stable
expression of 5Htt RNA in astrocyte cell cultures, there was no
signiﬁcant change of its expression upon incubation with either
antidepressant (not shown).
DISCUSSION
In the present study we demonstrated that treatment of primary
astroglial cell culture isolated from new born rats with the anti-
depressant imipramine leads to an acute increase of Bdnf RNA
expression. These data are in line with experiments on human
tissue showing evidence for glial pathology, both in the patho-
genesis of mood disorders as well as in the therapeutic effects of
antidepressants (Hisaoka et al., 2011; Kim et al., 2011). In post-
mortem brain-tissue from human patients having suffered from
major depression not only alterations in number and morphol-
ogy in neuronal cells can be found,but also even more prominent
changes in glial cells, especially astrocytes. The latter seem to be
altered in size and number in MDD patients (Hercher et al.,2009;
Altshuleretal.,2010).However,whetherglialpathologyisamajor
causeofmooddisordersorratheraconsequenceofneuronalalter-
ations is not clear at present. Astrocytes have been shown to not
onlyprovidemetabolicandtrophicsupportforneuronsbutalsoto
modulatelevelsof neurotransmittersandtosynthesizeandrelease
neurotrophic factors such as BDNF, glial cell-line derived neu-
rotrophic factor (GDNF) and ﬁbroblast growth factor 2 (FGF-2),
and thus play an important role in adult neurogenesis (Hisaoka
etal.,2007,2011;RajkowskaandMiguel-Hidalgo,2007).Notonly
do astrocytes synthesize neurotrophic factors, they also express
neurotransmitter receptors and monoamine transporter proteins,
atleastinvitro (DuffyandMacVicar,1995;Kangetal.,1998;Shel-
tonandMcCarthy,2000)whichledustoexaminetheexpressionof
the respective genes upon antidepressant treatment. Accordingly,
weheredetectedanexpressionofthemonoaminetransporter5Htt
as well as the neurotrophic factor Bdnf. Our key ﬁnding was stim-
ulated expression of the latter upon treatment with imipramine.
Deﬁciencies in neurotrophic factors and subsequent reduction in
neuronal resilience in the hippocampus may be an important ele-
ment in the pathophysiology of major depression (Nibuya et al.,
1995; Calabrese et al., 2011; Reus et al., 2011; Wolkowitz et al.,
2011). Recently it has been shown that imipramine treatment in a
mouse model of traumatic brain injury improved cognitive func-
tioning probably by increasing the survival of newly generated
neurons in the hippocampus (Han et al., 2011). Importantly, the
long-term survival of those newly generated neuronal cells crit-
ically depends on BDNF (Lee et al., 2002). It is well established
that treatment with antidepressant medication increases levels of
BDNF,which is clinically associated with the reduction of depres-
sive symptoms and responsiveness to medication (Chen et al.,
2001; Teixeira et al., 2010). In the current study we hypothesized
that the increase of Bdnf RNA after treatment with antidepressant
agents is partly due to astroglial cells. It is well known that anti-
depressant agents lead to acute molecular consequences, such as
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the increase of serotonin in the synaptic cleft, but the symptom
reductioninthetreateddepressedpatienttakesupto3weeks.The
molecular mechanisms underlying this delayed clinical effect of
treatment are still largely unknown. One hypothesis suggests that
stimulated serotonin and noradrenalin receptors activate intra-
cellular signaling pathways including the cAMP–CREB-cascade
which then regulates the expression of BDNF, thereby leading to
a higher rate of survival of newly generated neurons in the hip-
pocampus. Engagement of these adaptive processes may explain
in part the latency of clinical effect after antidepressant admin-
istration (Nibuya et al., 1996; van Praag et al., 2002; Duman,
2004).Therefore,anacuteincreaseof BDNFtriggeredfromastro-
cytes might be the starting point of a cascade which then leads to
neuroadaptive processes underlying therapeutic response.
Consistent with our hypothesis, we demonstrated that treat-
ment with imipramine for 4h signiﬁcantly increased the levels of
Bdnf RNA in astrocyte cell culture. After 24h treatment we could
however not detect any signiﬁcant changes in the levels of Bdnf
RNA compared to untreated cells (data not shown) suggesting
that the expressional regulation of Bdnf is an acute effect, which
initiatesotheradaptiveprocesses.Theseﬁndingsprovideevidence
that not only chronic, but also acute antidepressant treatment
elicits an increase in expression of Bdnf RNA or BDNF protein
level. Our point to the hypothesis that an acute increase in BDNF
is caused by astroglial cells and that this leads to the chronic
effects of antidepressant treatment,e.g.,the enhancement of adult
neurogenesis.
As astrocytes are in close contact with cerebral vasculature to
regulate the neuronal microenvironment, it has also been sup-
posed that astroglia might regulate the blood ﬂow of the brain via
release of nitric oxide probably produced by NOS-III (Wiencken
and Casagrande, 1999). It was shown that astrocytes synthesize
NOS-II after brain injury (Murphy et al., 1993). The failure to
detect any relevant amount of Nos3 RNA in astrocytes in the
presentstudyhoweverisconsistentwithearlierﬁndingsfromGath
etal.(1999),whowerealsounabletodemonstrateanyNOSstain-
ing in glial ﬁbrillary acidic protein positive astroglial cells derived
fromPCC7-Mz1embryoniccarcinomacells,whichhoweverisnot
at par with a study detecting NOS3 mRNA expression in human
astrocytoma T67 cells (Colasanti et al., 1998; Hamby et al., 2008).
However,ithastobetakenintoaccountthatcancercellsshowadif-
ferential expressional proﬁle probably explaining these discrepant
ﬁndings. In our study,we used untransformed primary astrocytes
to preserve in vivo properties as much as possible. Taken together,
astrocytes do not seem to express NOS-III and the only relevant
source of this protein in the brain most likely is endothelium.
Furthermore,we have investigated whether monoamine trans-
porters are expressed in astrocytes and if so, if this is changed
by antidepressant treatment. Some antidepressants also possess
dopaminergic mechanisms of action, e.g., bupropion, and triple
reuptake inhibitors (i.e., substances inhibiting serotonin, norep-
inephrine, and dopamine reuptake) are on the verge of entering
the market, and hence we not only tested for 5Htt, but also the
Dat. While Karakaya and associates (Takeda et al.,2002; Karakaya
et al., 2007) demonstrated Dat expression in astrocytes, several
other studies stated that the dopamine transporter can be nearly
exclusively found in neuronal cells (Torres et al., 2003; Dahlin
et al., 2007) which is consistent with the present study where
we could not detect any relevant Dat RNA expression. However,
it has to be said that there are presumably several subtypes of
astroglialcellsdifferinginspeciﬁcproteinexpression,localization,
and function which could explain these discrepancies (Halassa
et al., 2007). In contrast, it has been shown that astrocytes in cul-
ture can take up serotonin and this can be blocked by SSRIs like
ﬂuoxetine (Bal et al., 1997; Inazu et al., 2001). It has therefore
been speculated that astrocytes participate in the mode of action
of this class of antidepressant drugs. In line with this,we detected
expression of 5Htt in astroglia however no signiﬁcant changes
in expression upon either escitalopram or imipramine treatment
were found.
Taken together, our data support the hypothesis that at least
some tricyclic antidepressants, such as imipramine, lead to up-
regulationof BDNFviaastroglialcells.Itcanthereforebeassumed
thatastrocytesplayanimportantroleinthemodeofactionofanti-
depressants and probably the pathophysiological mechanisms of
mood disorders in general.
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